Farallon Capital Management LLC Buys Shares of 2,000 TransMedics Group, Inc. (NASDAQ:TMDX)

Farallon Capital Management LLC purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,000 shares of the company’s stock, valued at approximately $301,000.

Other large investors have also modified their holdings of the company. Xponance Inc. bought a new position in TransMedics Group in the 2nd quarter worth about $306,000. Hood River Capital Management LLC acquired a new position in shares of TransMedics Group during the second quarter worth approximately $18,854,000. Canada Pension Plan Investment Board bought a new position in TransMedics Group in the 2nd quarter worth approximately $16,086,000. SkyOak Wealth LLC acquired a new stake in TransMedics Group in the 2nd quarter valued at approximately $243,000. Finally, Amalgamated Bank raised its stake in TransMedics Group by 6.7% during the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after acquiring an additional 70 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Activity

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $8,948,714.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $145.17, for a total value of $1,252,091.25. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,948,714.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James R. Tobin sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the sale, the director now owns 173,146 shares of the company’s stock, valued at $27,587,352.18. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 61,247 shares of company stock worth $9,650,880. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $159.50 on Tuesday. The company has a market capitalization of $5.25 billion, a PE ratio of -469.12 and a beta of 1.99. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37. The stock has a fifty day moving average of $155.95 and a 200-day moving average of $130.14. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The firm had revenue of $114.30 million during the quarter, compared to analyst estimates of $98.84 million. During the same quarter last year, the business posted ($0.03) EPS. The company’s revenue was up 117.7% on a year-over-year basis. As a group, equities analysts anticipate that TransMedics Group, Inc. will post 1.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on TMDX shares. Morgan Stanley increased their price target on TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Needham & Company LLC assumed coverage on shares of TransMedics Group in a research note on Wednesday, August 21st. They set a “buy” rating and a $208.00 target price on the stock. Canaccord Genuity Group upped their price target on shares of TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Cantor Fitzgerald started coverage on shares of TransMedics Group in a research note on Thursday, June 6th. They set an “overweight” rating and a $161.00 price objective on the stock. Finally, Piper Sandler upped their target price on TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $171.44.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.